Love R R
Cancer Prevention Program, Wisconsin Clinical Cancer Center, Madison.
Oncology (Williston Park). 1992 Jul;6(7):33-8; discussion 38-40, 43.
An increasing body of data suggests that tamoxifen can suppress development of preclinical breast cancer. Newer data in postmenopausal women also demonstrate major biologic effects of tamoxifen on risk factors for cardiovascular disease and osteoporosis. Taken together, this information supports the hypotheses that use of tamoxifen will provide overall health benefits and lower the incidence of breast cancer in selected women, particularly postmenopausal women, who are willing to take a daily hormone pill indefinitely and who do not develop significant symptomatic side effects. Clinical trials addressing these hypotheses are beginning in the United States, Great Britain, and Italy, but the design and completion of such trials present significant challenges. Until clear data are available from the clinical trials just being launched, tamoxifen should not be given to healthy women who do not have breast cancer.
越来越多的数据表明，他莫昔芬可以抑制临床前乳腺癌的发展。绝经后女性的最新数据也显示，他莫昔芬对心血管疾病和骨质疏松症的风险因素具有重要的生物学作用。综合来看，这些信息支持了这样的假设，即使用他莫昔芬将为特定女性，尤其是绝经后女性带来整体健康益处，并降低乳腺癌的发病率，这些女性愿意无限期服用每日激素药丸且不会出现明显的症状性副作用。美国、英国和意大利正在开展针对这些假设的临床试验，但此类试验的设计和完成面临重大挑战。在刚刚启动的临床试验获得明确数据之前，不应将他莫昔芬给予没有乳腺癌的健康女性。
